Want to see BNTC full AI Analyst Report?
Top Page
Benitec Biopharma
(NASDAQ:BNTC)
Select Model
Select Model
Rating:47Neutral
Price Target:
$9.50
▼(-27.04% Downside)
Action:Reiterated
Date:09/24/26
BNTC scores low primarily due to weak financial performance (pre-revenue with large losses and ongoing cash burn), with bearish technical trends reinforcing near-term risk. A strong, low-debt balance sheet provides some support, but valuation metrics are limited by negative earnings and no dividend.
Positive Factors
Proprietary ddRNAi Platform
A focused ddRNAi platform and related intellectual property provide a specialized foundation for developing genetic medicines. If clinical programs demonstrate efficacy, this technology focus could support differentiated products and create longer-term strategic value beyond any single candidate.
Negative Factors
Pre-Revenue Business Model
The absence of meaningful revenue means the company has not yet demonstrated commercial traction or an operating revenue base. Continued dependence on development milestones rather than product sales makes financial performance highly uncertain over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ddRNAi Platform
A focused ddRNAi platform and related intellectual property provide a specialized foundation for developing genetic medicines. If clinical programs demonstrate efficacy, this technology focus could support differentiated products and create longer-term strategic value beyond any single candidate.
Read all positive factors
Benitec Biopharma (BNTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$334.18M
Dividend Yield0.12%
Average Volume (3M)154.01K
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue GrowthN/A
EPS Growth14.04%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.98
Shares Outstanding34,882,725
10 Day Avg. Volume208,275
30 Day Avg. Volume154,010
Financial Highlights & Ratios
PEG Ratio2.05
Price to Book (P/B)3.52
Price to Sales (P/S)0.00
P/FCF Ratio-37.48
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.67Price Target Upside89.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.15
Revenue Forecast (FY)N/A
Benitec Biopharma Business Overview & Revenue Model
Company Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines...
How the Company Makes Money
null...
Benitec Biopharma Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 75.00K | 73.00K |
| Gross Profit | -481.00K | -396.00K | -343.00K | 75.00K | 64.00K |
| EBITDA | -50.71M | -41.37M | -22.15M | -18.70M | -17.78M |
| Net Income | -45.55M | -37.92M | -21.75M | -19.56M | -18.21M |
Balance Sheet | |||||
| Total Assets | 182.62M | 99.59M | 52.21M | 4.46M | 5.97M |
| Cash, Cash Equivalents and Short-Term Investments | 179.97M | 97.74M | 50.87M | 2.48M | 4.06M |
| Total Debt | 762.00K | 849.00K | 284.00K | 559.00K | 811.00K |
| Total Liabilities | 5.61M | 2.30M | 4.96M | 4.26M | 3.09M |
| Stockholders Equity | 177.01M | 97.30M | 47.25M | 202.00K | 2.88M |
Cash Flow | |||||
| Free Cash Flow | -16.62M | -23.61M | -19.58M | -18.01M | -15.91M |
| Operating Cash Flow | -16.52M | -23.59M | -19.40M | -18.01M | -15.90M |
| Investing Cash Flow | -105.00K | -18.00K | -179.00K | -1.00K | -13.00K |
| Financing Cash Flow | 98.98M | 70.48M | 68.03M | 16.02M | 0.00 |
Benitec Biopharma Technical Analysis
Negative
13.02
Price Trends
11.94
Negative
11.93
Negative
11.90
Negative
Market Momentum
-0.80
Positive
27.49
Positive
16.45
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Negative. The current price of 13.02 is above the 20-day moving average (MA) of 10.90, above the 50-day MA of 11.94, and above the 200-day MA of 11.90, indicating a bearish trend. The MACD of -0.80 indicates Positive momentum. The RSI at 27.49 is Positive, neither overbought nor oversold. The STOCH value of 16.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTC.
Benitec Biopharma Risk Analysis
Benitec Biopharma disclosed 68 risk factors in its most recent earnings report. Benitec Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Benitec Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $764.58M | -5.03 | -41.33% | ― | 278712.12% | 26.59% | |
54 Neutral | $626.38M | -3.42 | -73.18% | ― | ― | 9.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $467.89M | 40.98 | -0.02% | ― | 125.12% | 98.69% | |
47 Neutral | $334.18M | -9.16 | -28.41% | 0.12% | ― | 14.04% | |
46 Neutral | $284.32M | -16.00 | -5.76% | ― | ― | 93.45% | |
45 Neutral | $16.54M | -0.41 | -145.40% | ― | -100.00% | 82.57% |
* Healthcare Sector Average
BNTC
Benitec Biopharma
8.98
-4.86
-35.12%
TVRD
Tvardi Therapeutics
1.15
-39.08
-97.14%
ASMB
Assembly Biosciences
22.54
-0.78
-3.34%
RCKT
Rocket Pharmaceuticals
2.56
-0.59
-18.73%
FDMT
4D Molecular Therapeutics
13.67
5.12
59.88%
AURA
Aura Biosciences Inc
6.09
0.04
0.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.